Is BioMarin Pharmaceuticals Stock a Buy?
BioMarin Pharmaceuticals (NASDAQ: BMRN) has not escaped the market sell-off caused by the COVID-19 pandemic. The stock dropped 21% from its high of $97.10, set March 4, before quickly rebounding; year to date, the biopharma's shares are down 5%. BioMarin is trading at 59.2 times future earnings, and the company's forward price-to-earnings-growth (PEG) ratio is 0.76. Given these valuation metrics, should investors consider buying shares?
BioMarin has a broad portfolio of commercialized drugs targeting rare genetic disorders. Marketed globally in more than 75 countries, these drugs offer steady revenue growth.
Image source: Getty Images.
Source Fool.com
